F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
57 hedge funds and large institutions have $73.5M invested in F-star Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
12% more funds holding
Funds holding: 51 → 57 (+6)
13% less capital invested
Capital invested by funds: $84.6M → $73.5M (-$11.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.81M |
| 2 |
BlackRock
New York
|
+$801K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$574K |
| 4 |
HP
Hikari Power
Tokyo,
Japan
|
+$474K |
| 5 |
FI
Fosun International
Hong Kong,
China
|
+$350K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$2.29M |
| 2 |
Jennison Associates
New York
|
-$1.71M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$856K |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$450K |
| 5 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$313K |
FSTX Hedge Fund Activity: Q4 2018 in Review
57 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q4 2018, worth a combined $73.5M — down 13% from $84.6M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new FSTX positions and 3 closed out — a net gain of 6 holders — while 20 added to existing stakes and 12 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $2.81M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $2.29M sold.
- 57 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q4 2018, up from 51 in Q3 2018.
- Funds reported $73.5M of F-star Therapeutics, Inc. Common Stock stock for Q4 2018, down 13% quarter-over-quarter.
- 9 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q4 2018 and 3 closed out, a net change of +6 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q4 2018 was Adage Capital Partners, an estimated $2.81M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q4 2018 was Sofinnova Investments, an estimated $2.29M sold.
Based on aggregated 13F filings for Q4 2018.